References
- Walsh G. Biopharmaceutical benchmarks 2010. Nat. Biotechnol. 28(9), 917–924 (2010).
- Goodman M. Market watch: sales of biologics to show robust growth through to 2013. Nat. Rev. Drug Discov. 8(11), 837 (2009).
- Reichert JM. Marketed therapeutic antibodies compendium. MAbs 4(3), 413–415 (2012).
- Reichert JM. Which are the antibodies to watch in 2013? MAbs 5(1), 1–4 (2013).
- Murad JP, Lin OA, Espinosa EV, Khasawneh FT. Current and experimental antibody-based therapeutics: insights, breakthroughs, setbacks and future directions. Curr. Mol. Med. 13(1), 165–178 (2013).
- Allen TM. Ligand-targeted therapeutics in anticancer therapy. Nat. Rev. Cancer 2(10), 750–763 (2002).
- Leon JA, Goldstein NI, Fisher PB. New approaches for the development and application of monoclonal antibodies for the diagnosis and therapy of human cancer. Pharmacol. Ther. 61(1–2), 237–278 (1994).
- Presta LG. Engineering of therapeutic antibodies to minimize immunogenicity and optimize function. Adv. Drug Deliv. Rev. 58(5–6), 640–656 (2006).
- Imai K, Takaoka A. Comparing antibody and small-molecule therapies for cancer. Nat. Rev. Cancer 6(9), 714–727 (2006).
- Veber DF, Johnson SR, Cheng HY, Smith BR, Ward KW, Kopple KD. Molecular properties that influence the oral bioavailability of drug candidates. J. Med. Chem. 45(12), 2615–2623 (2002).
- Christiansen J, Rajasekaran AK. Biological impediments to monoclonal antibody-based cancer immunotherapy. Mol. Cancer Ther. 3(11), 1493–1501 (2004).
- Waltz E. GlaxoSmithKline cancer drug threatens Herceptin market. Nat. Biotechnol. 23(12), 1453–1454 (2005).
- Wurch T, Pierré A, Depil S. Novel protein scaffolds as emerging therapeutic proteins: from discovery to clinical proof-of-concept. Trends Biotechnol. 30(11), 575–582 (2012).
- McEnaney PJ, Parker CG, Zhang AX, Spiegel DA. Antibody-recruiting molecules: an emerging paradigm for engaging immune function in treating human disease. ACS Chem. Biol. 7(7), 1139–1151 (2012).
- Wu AM, Senter PD. Arming antibodies: prospects and challenges for immunoconjugates. Nat. Biotechnol. 23(9), 1137–1146 (2005).
- Imai K, Takaoka A. Comparing antibody and small-molecule therapies for cancer. Nat. Rev. Cancer 6(9), 714–727 (2006).
- Carlson CB, Mowery P, Owen RM, Dykhuizen EC, Kiessling LL. Selective tumor cell targeting using low-affinity, multivalent interactions. ACS Chem. Biol. 2(2), 119–127 (2007).
- Huang H, Lai JY, Do J et al. Specifically targeting angiopoietin-2 inhibits angiogenesis, Tie2-expressing monocyte infiltration, and tumor growth. Clin. Cancer Res. 17(5), 1001–1011 (2011).
- Kodadek T. Protein binding: antibody surrogates click into place. Nat. Chem. 1(3), 183–185 (2009).
- Oyelaran O, McShane LM, Dodd L, Gildersleeve JC. Profiling human serum antibodies with a carbohydrate antigen microarray. J. Proteome Res. 8(9), 4301–4310 (2009).